1. HBW Insight

FDA To Hanbul Cosmetics: You’re Marketing Noncompliant Drugs

 
• By Ryan Nelson

The agency’s warning letter cites the Korean firm, whose offering includes sunscreen and skin-whitening products, for violations of drug CGMP regulations. Problems identified during a recent inspection include microbiological testing failures and questions about equipment quality.

Vintage inscription made by old typewriter, warning

Korean firm It’S Hanbul Co., Ltd., dba Hanbul Cosmetics, must report back to FDA about corrective measures it’s taken since a late 2017 inspection that found “significant” violations of current good manufacturing practices (CGMP) regulations for finished pharmaceuticals.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation